What is Cardeas Pharma?
Cardeas Pharma is a privately held biopharmaceutical company focused on developing and commercializing inhaled antibiotics. Their core strategy involves combining novel formulations of established antibiotics with advanced drug delivery technology to address critical unmet medical needs, particularly in treating infections caused by highly antibiotic-resistant organisms within the critical-care setting. The company's approach aims to provide effective solutions for severe respiratory ailments in hospital environments.
How much funding has Cardeas Pharma raised?
Cardeas Pharma has raised a total of $41.5M across 2 funding rounds:
Series A
$7.5M
Series B
$34M
Series A (2012): $7.5M, investors not publicly disclosed
Series B (2013): $34M led by H.I.G. BioVentures, LLC, Avalon Ventures, Washington Research Foundation, Novo A/S, Devon Park Bioventures, and Delphi Ventures
Key Investors in Cardeas Pharma
H.I.G. BioVentures, LLC
H.I.G. BioVentures, LLC is a venture capital arm of H.I.G. Capital, a global alternative investment firm with a strong focus on the mid-cap segment. They specialize in growth equity and private equity investments, particularly within the healthcare sector, aiming to support companies like Cardeas Pharma in their scaling and commercialization efforts.
Avalon Ventures
Avalon Ventures is a venture capital firm with extensive experience in seed and early-stage investments, particularly in life sciences and information technology. Their focus on disruptive ideas and building strong relationships suggests a strategic interest in Cardeas Pharma's innovative approach to antibiotic development.
Novo A/S
Novo A/S, through Novo Holdings, is a Danish investment company wholly owned by the Novo Nordisk Foundation. Their involvement indicates a significant backing from a major player in the global healthcare and life sciences industry, likely aligning with Cardeas Pharma's mission to address critical medical needs.
What's next for Cardeas Pharma?
The substantial enterprise-level funding and recent strategic investment indicate a pivotal growth phase for Cardeas Pharma. This capital infusion is expected to accelerate the development and commercialization of their inhaled antibiotic therapies. The company is likely to focus on advancing its pipeline through clinical trials, scaling manufacturing capabilities, and preparing for market entry. Strategic partnerships and further financing rounds may also be on the horizon as Cardeas Pharma solidifies its position in the biopharmaceutical market for critical-care respiratory infections.
See full Cardeas Pharma company page
